Oncology Business Management

Since it's implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and other diseases expanded access to affordable medications by selling drugs at discounted prices to eligible centers.

Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Medicare drug price negotiations may impact community oncology practices, leading to potential changes in drug access, reimbursement, and patient care strategies.

Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the examination of scans, and more.

Debra Patt, MD, PhD, MBA, FASCO, highlights considerations with financial burdens that will be placed on community providers and oncology practices.

Jeff Patton, MD, details considerations with the Medicare Drug Price Negotiation Program Draft Guidance and its effects in the community setting.

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Kassem Faraj, MD, details the 340B Drug Pricing program and data from a study examining participation in the program for patients with advanced prostate cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.

Manmeet Singh Ahluwalia, MD, and his wife, Harneet Kaur Walia, MD, say that they learn from each other’s experiences and share in successes.

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.

As genomic testing becomes ubiquitous in cancer care, some patients experience out-of-pocket costs that may affect oncologists’ genetic testing decisions.

Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.

The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.

A possible cause of some of the cost-related delays and nonadherence to treatment that patients with cancer and cancer survivors experience could be the time and effort they are forced to spend on administrative payment tasks related to their care.

A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.